Home
overview

Considerable progress has been made in immunogenicity over recent years, with innovative developments seen in predicting and controlling immunogenicity. Complex challenges to industry remain however.

At SMi’s 4th annual Immunogenicity conference, industry, regulatory and academic experts will gather to spark debate and progress on the causes of immunogenicity, predicting and preventing its effects, and its associated issues. Immunogenicity 2017 will offer unparalleled networking opportunities, deep insight into industry issues, and spotlight sessions on innovations and emerging technologies for immunogenicity.

Immunogenicity 2017 will explore the need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. We will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for our delegates, Immunogenicity 2017 will highlight and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.

• Guidance on UK and EU regulations surrounding immunogenicity and best practice risk assessment
• Targeted focus on immunogenicity; identifying, addressing and removing challenges to industry
• Highlight best practise risk assessment and mitigation through high level case studies
• Explore novel and innovative approaches to reducing immunogenicity
• Spotlight on new technology; Humanising proteins and new biotherapeutic solutions
• Personalising treatments with next generation biologic drugs
 

Directors, Group Leaders, Department Heads, Senior Scientists of: 

  • Immunogenicity
  • Immunology
  • Regulatory Affairs
  • Biologic Drugs
  • Pre Clinical Risk Assessment
  • Drug Development
  • Clinical Development

Abzena; Accord Healthcare; Baliopharm AG; Baxalta; Bioarctic Neuroscience; Bristol Myers Squibb; Crucell Vaccine Institute; EpiVax, Inc.; F.Hoffmann-La Roche AG; Free University Of Brussels; GSK; ImmunXperts; ISA Pharmaceuticals; mAbxience; Medimmune LLC; National Institute for Biological Standards and Control; Netera AS; NEXTERA AS; NIBSC; Pfizer; Pfizer Pharmaceuticals; ProImmune Ltd.; Public Health England; Selecta Biosciences; SGS CEPHAC EUROPE SAS; Smithers Avanza; Teva; TIGENIX SAU; UCB; University Of Manchester;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Oreda Boussadia

Oreda Boussadia, European Head of Business Development and Strategy , EpiVax, Inc.
View Bio

9:10 The ABIRISK project: an integrated approach to assess predictive markers of immunogenicity

Sophie Tourdot

Sophie Tourdot, Scientific Project Manager, INSERM
View Bio

• ADA assays standardisation
• Predictive tools
• Biomarkers identification
• Integrative prediction

9:50 Reporting of clinically relevant immunogenicity data for low risk molecules

Albert Torri

Albert Torri, Executive Director, Bioanalytical Sciences, Regeneron
View Bio

• Immunogenicity assays have become more sensitive and drug tolerant in recent years resulting in the detection of low titer, transient ADA responses which previously were not detected
• Low risk, fully human MAbs often generate mostly low titer, transient ADA responses which have little to no clinical relevance
• Reporting incidence of total ADA in these cases is not that informative since it may not be clinically relevant and does not guide practice
• Identifying and reporting the most clinically relevant ADA responses which are more likely to impact efficacy or safety would be more informative to both patients and health care providers

10:30 Morning Coffee

11:00 Cut point setting in the presence of pre-existing anti-drug antibodies

Matthias Hofmann

Matthias Hofmann, Senior Investigator, Novartis Institutes for BioMedical Research
View Bio

• Conventional methods for cut point (CP) setting may fail in case a considerable number of sera used for method validation contain pre-existing anti-drug antibodies (ADA). This would result in an overestimation of the CP and thus underestimation in the number of ADA positive samples within the examined study population
• Separating ADA positive and negative samples already during method validation by modelling two (or more) overlaying populations and using only the ADA negative population for CP setting proved to be a viable method to tackle this challenge
• Details on and limitations of the method will be discussed, as well as several examples be presented

11:40 Perspectives on EU immunogenicity guidance and data reporting

Meenu Wadhwa

Meenu Wadhwa, Section Leader, Cytokines & Growth Factors Section, NIBSC
View Bio

• Overview of revised EU guidance
• Harmonising information on immunogenicity assays and clinical reporting
• Challenges with immunogenicity assessments for biosimilars

12:20 Networking Lunch

13:30 ADA-Dependent hypersensitivity reactions in preclinical toxicology studies

Rob Caldwell

Rob Caldwell, Principal Research Scientist, Regulatory Toxicology, AbbVie
View Bio

• Prevalent adverse immunogenic responses observed during preclinical toxicology studies resulting in regulatory challenges for clinical trial progression
• Dedicated preclinical studies were conducted to further characterize mechanism of adverse responses
• Results of these experiments will be presented, with the outcome of regulatory acceptance and changes to internal best practices for parenterally administered biologic compounds will be discussed

14:30 Personalizing biologic therapy: In silico methods for risk assessment

Annie De Groot

Annie De Groot, CEO and CSO, EpiVax, Inc.

• A case study: ADA in Pompe patients 

14:50 Afternoon Tea

15:20 Preclinical and early development of tolerogenic nanoparticles to mitigate the formation of anti-drug antibodies

Kei Kishimoto

Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc.

• Novel and universal approach to mitigate immunogenicity of biologic drugs
• Anti-specific immune tolerance
• Case study-clinical data for a combination product consisting of tolerogenic nanoparticles with a pegylated uricase for the treatment of chronic refractory gout

16:00 Immunogenicity from basic immunology towards pragmatic solutions

Louis Boon

Louis Boon, Chief Scientific Officer, Bioceros

• Humanization and selection of lead humanized version
• Cell line and process development
• Functional ADA bioassays

16:40 Chairman’s Closing Remarks and Close of Day One

Oreda Boussadia

Oreda Boussadia, European Head of Business Development and Strategy , EpiVax, Inc.
View Bio

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Oreda Boussadia

Oreda Boussadia, European Head of Business Development and Strategy , EpiVax, Inc.
View Bio

9:10 Immunogenicity prediction tools: how close are we to predicting outcomes in clinic?

Vibha Jawa

Vibha Jawa, Director of Biologics and Vaccines Development , Merck
View Bio

• Overview of available predictive tools for biologics
• Layering of tools to increase accuracy of the clinical outcome
• Implementing a strategy in discovery phase to select better candidates

9:50 The impact on immunogenicity risk assessment – impact on bioanalytical strategies in determining immunogenicity

John  Smeraglia

John Smeraglia , Senior Director, Bioanalytical Sciences , UCB
View Bio

• Assessing risk of immunogenicity at each stage of development
• Bioanalytical strategies in pre-clinical and clinical development
o Robust assay development/ characterization
o Pre-study validation and in study validation
• Challenges associated with multi-domain biologics

10:30 Morning Coffee

11:00 Immunogenicity assessment in biosimilar clinical trials with a monoclonal antibody

Ivo Sonderegger

Ivo Sonderegger , Project Manager , Boehringer Ingelheim
View Bio

• Immunogenicity-assay format for assessing anti-drug-antibodies in biosimilar trials
• Assay validation and cut-point determination for ADA assays
• Assessment of comparative clinical immunogenicity
• Challenges associated with biosimilar clinical trials

11:40 Challenges of in vitro immunogenicity risk assessment: case study of Nanobodies

Chloe Ackaert

Chloe Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University Of Brussels

• Are all DCs the same? 
• Can the same construct give different immunogenicity risk outcomes?
• Is humanisation always wanted?

12:20 Networking Lunch

13:30 Immunogenicity risk of 2nd generation biosimilars: from fear-mongering to fact-finding

Uwe Gudat

Uwe Gudat, Head of Safety Biosimilars, Merck Serono

• The principle paradigm: structure determines function
• Prior probabilities and sources of uncertainty
• Towards an informed and disciplined discussion

14:10 De-risking antibodies in early development

Katharine Bray-French

Katharine Bray-French, Toxicology Project Leader, F. Hoffmann La-Roche
View Bio

• Application of in vitro early development
• Case studies with clinical antibodies

14:50 Afternoon Tea

15:20 Unwanted immunogenicity of immuno-oncology drugs

Sofie Pattijn

Sofie Pattijn, Chief Technology Officer, ImmunXperts

• Immune checkpoint-based immunotherapy has shown remarkable clinical benefits in a variety of cancer diseases but these new treatment modalities can also induce an array of immune-related adverse effects such as induction of auto-immunity and anti-drug-antibody based anaphylaxis
• Early tools like in silico and in vitro immunogenicity assessment tests should be applied during the development phase in order to avoid any risk of unwanted immunogenicity

16:00 An integrated approach to managing immunogenicity risk and drug immune modulation

Jeremy Fry

Jeremy Fry, Director of Sales, ProImmune Ltd.
View Bio

• Learn how data from cell-based assays, physical MHC-peptide binding assays and mass spectrometry antigen presentation assays can be integrated to characterize immune responses against, or caused by, bio therapeutic drugs
• Mitigate the risk of first infusion reactions using whole-blood cytokine release assays.
• Improve decision-making in lead selection, lead characterisation and re-engineering options

16:40 Panel discussion: cancer (immunosuppressive) vs. autoimmunity (inflammatory

Louis Boon

Louis Boon, Chief Scientific Officer, Bioceros

Sofie Pattijn

Sofie Pattijn, Chief Technology Officer, ImmunXperts

Annie De Groot

Annie De Groot, CEO/CSO, EpiVax, Inc.

17:20 Chairman’s Closing Remarks and Close of Day Two

Oreda Boussadia

Oreda Boussadia, European Head of Business Development and Strategy , EpiVax, Inc.
View Bio

+

FEATURED SPEAKERS

Albert Torri

Albert Torri

Executive Director, Bioanalytical Sciences, Regeneron
Katharine Bray-French

Katharine Bray-French

Toxicology Project Leader, F. Hoffmann La-Roche
Kei Kishimoto

Kei Kishimoto

Chief Scientific Officer, Selecta Biosciences Inc.
Oreda Boussadia

Oreda Boussadia

European Head of Business Development and Strategy , EpiVax, Inc.
Sofie Pattijn

Sofie Pattijn

Chief Technology Officer, ImmunXperts
Sophie Tourdot

Sophie Tourdot

Scientific Project Manager, INSERM
Vibha Jawa

Vibha Jawa

Director of Biologics and Vaccines Development , Merck

Albert Torri

Executive Director, Bioanalytical Sciences, Regeneron
Albert Torri

Albert Torri is the Executive Director of Bioanalytical Sciences at Regeneron Pharmaceuticals in Tarrytown, NY. He received his Ph.D. in Biochemistry from the University of Alabama at Birmingham and conducted his post-doctoral studies at Johns Hopkins University. He then joined the Bristol-Myers Squibb Company where he served as a Senior Research Investigator and member of the Discovery Working Group. In his current position at Regeneron Pharmaceuticals, he directs assay development and bioanalytical activities. Responsibilities include the development, validation and automation of PK, PD and immunogenicity assays to support preclinical and clinical studies of biologics, as well as the bioanalysis of all preclinical and clinical study samples using these assays.

Annie De Groot

CEO/CSO, EpiVax, Inc.
Annie De Groot

Chloe Ackaert

Postdoctoral Researcher, Cellular and Molecular Immunology, Free University Of Brussels
Chloe Ackaert

Ivo Sonderegger

Project Manager , Boehringer Ingelheim
Ivo Sonderegger

Ivo Sonderegger is a DMPK Project Manager at Boehringer Ingelheim Pharma in Ingelheim am Rhein (Germany). He received his Ph.D. in Immunology from the Swiss Federal Insitute of Technology (Zürich, Switzerland) in the field of cytokine immunology. He then joined Molecular Partners AG in (Zürich, Switzerland) where he was responsible for in-vivo and in-vitro pharmacology in the R&D Department. He was also served as non-clinical pharmacokineticist and was a key contributor in the immunogenicity risk-assessment of the DARPin platform. In his current position at Boehringer Ingelheim Pharma, he is responsible for the non-clinical and clinical immunogenicity evaluation for biosimilar compounds. He directs assay development and validation of PK, ADA, and neutralizing antibody assays and manages bioanalytical testing activities for clinical trials of biosimilar compounds. Furthermore Ivo is responsible for the non-clinical pharmacology assays regarding similarity assessment of biosimilar compounds.

Jeremy Fry

Director of Sales, ProImmune Ltd.
Jeremy Fry

Jeremy Fry gained his DPhil. from the University of Oxford developing gene therapy strategies to induce immunological tolerance in transplant recipients. Jeremy joined ProImmune to generate a new class of MHC multimer staining reagents. For the past 14 years as ProImmune's Director of Sales, he has led the sales team in a growing business, focusing on technologies that radically improve our understanding of immune responses.

John Smeraglia

Senior Director, Bioanalytical Sciences , UCB
John  Smeraglia

John is the Senior Director of Bioanalytical Sciences in Non-Clinical Development at UCB with laboratories in the UK and Belgium. He has responsibilities for bioanalytical sciences to enhance and revolutionize the way that the quantitative bioanalysis is performed from pre-clinical development to post marketing for NBE’s and NCE’s . He is also responsible for providing bioanalytical leadership for Pharmacokinetic and Immunogenicity testing to advance drug development. John has held bioanalytical leadership positions in the US and EU with innovator drug development companies and CROs. He obtained his first degree in Medical Technology in the US and his second degree in Biomedical Sciences in the UK where his thesis focus on diagnostic markers in the treatment and management of diabetic nephropathy. His has developed his experience in bioanalytical sciences for the last 25 years and is the author of more than 30 peer reviewed publications.

Katharine Bray-French

Toxicology Project Leader, F. Hoffmann La-Roche
Katharine Bray-French

Katharine Bray-French is a Senior Principal Scientist at Roche Ltd, Switzerland. She received her PhD from Manchester University, UK and subsequently moved to Basel, Switzerland, where she has gained considerable experience in drug development, working at both large and small pharmaceutical companies and at a CRO, over the last 20 years. As a Toxicology Project Leader within Pharmaceutical Sciences at Roche, Katharine is involved in the development of nonclinical strategies for large and small molecules, specifically relating to the safety of novel immune therapies and immune therapy combinations, for oncology and rare disease indications.

Kei Kishimoto

Chief Scientific Officer, Selecta Biosciences Inc.
Kei Kishimoto

Louis Boon

Chief Scientific Officer, Bioceros
Louis Boon

Matthias Hofmann

Senior Investigator, Novartis Institutes for BioMedical Research
Matthias Hofmann

1992 – 1999: Diploma in Biochemistry (Studies in Würzburg, Germany, Tübingen, Germany & Austin, TX, USA)
1999 – 2002: PhD in Immunology (University of Tübingen)
2002 – 2005: PostDoc in Transplanation Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
2005 – present: LabHead in Bioanalytics & Immunogenicity, Novartis Institutes for BioMedical Research, Basel, Switzerland

Meenu Wadhwa

Section Leader, Cytokines & Growth Factors Section, NIBSC
Meenu Wadhwa

Meenu Wadhwa is Section Leader, Cytokines and Growth Factors Section in the Biotherapeutics Group at the National Institute for Biological Standards and Control (NIBSC). She is responsible for a number of diverse projects in the cytokine and growth factor area. These include preparation of cytokine standards and/or reference reagents for WHO and Pharmacopoeias, development, and implementation of cytokine assays and their use in standardization, product testing and in research. Main research interests include development of novel bioassays for cytokines, cytokine contamination of biological products and the unwanted immunogenicity of biotherapeutic products. This has resulted in over 90 publications in scientific journals/books and several presentations at international/ national scientific conferences. She has contributed to several guidelines, for example, the drafting of the EMA guidelines on immunogenicity assessment and WHO guidelines on Evaluation of Similar Biotherapeutic Products. She reviews manuscripts for several scientific journals and is currently an editorial board member for Journal of Immunological Methods and an associate editor for Biologicals.

Oreda Boussadia

European Head of Business Development and Strategy , EpiVax, Inc.
Oreda Boussadia

Oréda is a Global and Corporate Executive Business Sales and Marketing Leader having experience in the biomedical research.
Experienced Science, Operations, Business, Sales and Marketing professional, driven to create value and achieve at the highest level within the Global CRO and Biotech markets. A visionary and a positive individual who embraces a culture of change. She continues to support innovative health industries with the need to strengthen to manage the business growth. Her main areas of expertise are: Global business awareness and market intelligence-define and implement business, sales, marketing and client service strategies-Develop of new products and services-Human resources management-Project management and organization-Define and implement operations strategy-Profitability and quality management. She is currently the European Head of Business Development and Strategy at Epivax - an immunology company that uses "immunoinformatics" computer modeling to develop new vaccines and to improve the immunogenicity profiles of new drugs. Before, Oréda was the Global Head of Sales, Marketing and Client services of Eurofins Pharma Discovery Services managing an annual revenue of $60M. She finalized the global organization within former Cerep, Panlabs, DDS-Millipore to build the Eurofins Pharma Discovery Services. Director of the Life Sciences Business Unit at Invest in Lyon she set up 22 foreign companies in Lyon region. Prior, Oréda was the Scientific Business Development Manager at Taconic Biosciences. During 3 years she built up a demand for Taconic offer and establish a solid brand in the smart solutions part of the French market. Taconic has seen its revenues increased by 32 % sales per year. As operations manager of the GEMS Genetically Engineered Model Services at Charles River France she achieved an annual increase of 30% EBITA and 16% of revenues . Before to join industries, she spent 10 years as a researcher in Max Planck Institute and in Gustave Roussy Institute, she has got 10 international research publications on cancer field http://www.ncbi.nlm.nih.gov/pubmed/.

Rob Caldwell

Principal Research Scientist, Regulatory Toxicology, AbbVie
Rob Caldwell

Rob is a toxicologist at AbbVie, where he has worked for the last 10 years. Rob’s main responsibility is to manage the preclinical toxicology strategy for drug development teams, supporting the overall safety assessment of new drugs. He works primarily on rheumatologic therapies but has also worked with antivirals and pain therapies. Prior to joining AbbVie, Rob worked at Covance Laboratories (a contract research laboratory) for 8 years where he lead the immunotoxicology program and conducted general toxicology studies for the pharmaceutical industry. Rob obtained his PhD in Immunology from Northwestern University in Chicago; where he studied mechanisms of Epstein-Barr virus latency and reactivation using transgenic mice.

Sofie Pattijn

Chief Technology Officer, ImmunXperts
Sofie Pattijn

Sophie Tourdot

Scientific Project Manager, INSERM
Sophie Tourdot

Sophie Tourdot received her Ph.D. in T cell vaccine immunology at the University of Paris. Following her postdoctoral trainings at Imperial College London, she worked at the Pasteur Institute on HIV vaccine design then progressed to Stallergenes and ITS, where she lead the Pre-clinical immunology teams. She currently works at Inserm as Scientific Project Manager for the IMI-funded ABIRISK project, a consortium of 38 partners from pharmaceutical companies and academic research centres across Europe, Israel and the United-States. The program focuses on the analysis of underlying biological mechanisms, clinical relevance and prediction of unwanted immunogenicity of biopharmaceuticals. Sophie Tourdot is also the Secretary General of the European Immunogenicity Platform.

Vibha Jawa

Director of Biologics and Vaccines Development , Merck
Vibha Jawa

Dr. Vibha Jawa is currently a Director, Biologics and Vaccine Bioanalytics at Merck where she is responsible for developing a strategy and provide oversight and management of scientific programs for discovery, development and optimization of biologics and vaccines. In this role, she is partnering with discovery and development groups to design better molecules. Her current research interests include evaluating immune response biomarkers for early drug development and efficacy, immunogenicity prediction using in silico, in vitro and in vivo technologies, modeling impact of immunogenicity on PK and PD, antigen processing and presentation and the role of T cells in immune response to drug products. Vibha has been actively involved in the American Association of Pharmaceutical Scientists (AAPS) as a Steering Committee member of the Therapeutic Protein Immunogenicity Focus Group (TPIFG) and currently is leading Immunogenicity Prediction Action Program Area (IPAPA). Dr Jawa obtained her Ph.D. in Biochemistry and Immunology with a thesis work studying the immune mechanisms behind autoimmune diseases followed by a postdoctoral fellowship at University of Pennsylvania on monitoring the immune response to viral vectors. She continued to work in the field of gene therapy company evaluating viral vectors for hemophilia therapy in the Bay area followed by City of Hope Cancer Centre Stem Cell and Gene Therapy group and at Amgen from 2003-2016.

Sponsors and Exhibitors

Workshops

Immunogenicity - from non-clinical detection to clinical impact
Workshop

Immunogenicity - from non-clinical detection to clinical impact

Holiday Inn Kensington Forum
14th June 2017
London, United Kingdom

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Sponsors and Exhibitors


SGS Cephac

Sponsors and Exhibitors
http://www.sgs.com/bioanalysis

SGS Cephac has a strong ImmunoAssay Department with strong experience in Immunogenicity Testing, including the use of the Immune Response Module of LIMS systems. SGS Cephac belongs to the SGS Life Science Network which is a leading Life Science bio/pharmaceutical, analytical and bioanalytical contract organization providing pharmaceutical development, biologics characterization, utilities qualification, biosafety, and quality control testing. Delivering solutions for pharmaceutical, biologics, and medical-device manufacturers, SGS offers GMP/GLP compliant contract laboratory services including analytical chemistry, microbiology, stability studies, bioanalysis, extractables and leachables, virology, and protein analysis. With 21 laboratories SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.